Structured evidence table for Niacin Lipid Profile Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Niacin Lipid Profile Randomized Trial | Elevated low-density lipoprotein cholesterol (LDL-C) is a key modifiable risk factor in atherosclerotic cardiovascular diseases. | 3 | Liu HH (2026) | A Comprehensive, Updated Review of Ezetimibe: Evidence-Based Clinical Use for Atherosclerotic Cardiovascular Disease. |
| Niacin Lipid Profile Randomized Trial | While statins are the first-line therapy for LDL-C management, challenges such as limited additional benefits with dose escalation and an increased risk of adverse drug reactions at higher doses remain. | 3 | Liu HH (2026) | A Comprehensive, Updated Review of Ezetimibe: Evidence-Based Clinical Use for Atherosclerotic Cardiovascular Disease. |
| Niacin Lipid Profile Randomized Trial | Ezetimibe monotherapy reduces LDL-C levels by approximately 17.1-25.9% and significantly lowers the risk of major adverse cardiovascular events compared with placebo. | 3 | Liu HH (2026) | A Comprehensive, Updated Review of Ezetimibe: Evidence-Based Clinical Use for Atherosclerotic Cardiovascular Disease. |
| Niacin Lipid Profile Randomized Trial | Since its discovery over half a century ago, Lp(a) has attracted considerable interest due to its strong, genetically determined association with atherosclerotic cardiovascular disease (ASCVD), independent of traditional lipid risk factors. | 4 | Domański Igor (2026) | Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update |
| Niacin Lipid Profile Randomized Trial | Elevated Lp(a) concentrations—particularly those above 50 mg/dL—have been strongly linked to an increased risk of myocardial infarction, ischemic stroke, peripheral artery disease, heart failure, and aortic valve stenosis. | 4 | Domański Igor (2026) | Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update |
| Niacin Lipid Profile Randomized Trial | There is a lot of evidence from studies of people that supports the idea that high levels of Lp(a) cause atherosclerosis, stroke and problems with the valves in the heart. | 4 | Domański Igor (2026) | Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update |
| Niacin Lipid Profile Randomized Trial | 1 Lipoprotein(a) [Lp(a)] is a lipoprotein particle structurally related to low-density lipoprotein (LDL), but characterized by the presence of an additional apolipoprotein(a) [apo(a)] component, covalently linked to apolipoprotein B-100 via a disulfide bond []. | 4 | Domański Igor (2026) | Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update |
Source documents